- Advertisement -
Sydney-based biotech Tetratherix (ASX: TTX) has advanced plans to take its universal bone regeneration technology to the global market after finalising an exclusive distribution agreement with Nasdaq-listed Henry Schein, Inc.
The company, which listed on the ASX in June last year following a…
Click here to view the original article.
